Sterling Capital Management LLC lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8,619.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,562 shares of the specialty pharmaceutical company's stock after purchasing an additional 14,395 shares during the period. Sterling Capital Management LLC's holdings in Supernus Pharmaceuticals were worth $527,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at approximately $6,847,000. Great Lakes Advisors LLC acquired a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $6,131,000. Norges Bank bought a new position in Supernus Pharmaceuticals during the fourth quarter worth about $4,540,000. American Century Companies Inc. grew its position in shares of Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after buying an additional 95,777 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Supernus Pharmaceuticals by 79.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 174,916 shares of the specialty pharmaceutical company's stock valued at $6,325,000 after acquiring an additional 77,393 shares during the period.
Supernus Pharmaceuticals Price Performance
Shares of Supernus Pharmaceuticals stock traded up $0.30 on Wednesday, hitting $31.14. The company had a trading volume of 75,447 shares, compared to its average volume of 492,533. The stock has a 50-day moving average of $32.41 and a 200-day moving average of $35.01. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The firm has a market capitalization of $1.74 billion, a P/E ratio of 29.10 and a beta of 0.90.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.
Get Our Latest Report on SUPN
Insider Buying and Selling
In other news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares of the company's stock, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company's stock.
Supernus Pharmaceuticals Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Further Reading
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
